Asako Horino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Asako Horino has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Hiroko Ikeda
Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka 420-8688, Japan
2 shared publications - Hiroshi Sakuma
Department of Brain Development and Neural Regeneration Tokyo Metropolitan Institute of Medical Science Tokyo Japan
2 shared publications - Hirotomo Saitsu
Department of Biochemistry Hamamatsu University School of Medicine Hamamatsu Japan
2 shared publications Hisashi Kawawaki
Department of Pediatric Neurology Children's Medical Center Osaka City General Hospital Osaka Japan
2 shared publicationsMegumi Nukui
Department of Pediatric Neurology Children's Medical Center Osaka City General Hospital Osaka Japan
2 shared publications- Mitsuhiro Kato
Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
2 shared publications
Latest Publications
- 15 June 2023
- Published by Elsevier in Brain Research
- Vol. 1815, 148463
Lipocalin-2 production by astrocytes in response to high concentrations of glutamate
- 15 June 2023
- Published by Elsevier in Brain Research
- Vol. 1815, 148463
Lipocalin-2 production by astrocytes in response to high concentrations of glutamate
- Open Access
- 26 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (13) , eabd2368
De novo ATP1A3 variants cause polymicrogyria
ATP1A3 , a mutated gene for AHC, RDP, and CAPOS, is also associated with polymicrogyria by different functional variants.
- 26 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (13) , eabd2368
Open AccessDe novo ATP1A3 variants cause polymicrogyria
ATP1A3 , a mutated gene for AHC, RDP, and CAPOS, is also associated with polymicrogyria by different functional variants.
- Open Access
- 5 February 2021
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 8 (3) , 645-655
Intrathecal dexamethasone therapy for febrile infection‐related epilepsy syndrome
Objective: Increasing reports suggest a role for immunological mechanisms in febrile infection‐related epilepsy syndrome (FIRES). The objective of this study was to elucidate the efficacy and safety of intrathecal dexamethasone therapy (IT‐DEX).Methods: We assessed six pediatric patients with FIRES who were administered add‐on IT‐DEX in the acute (n = 5) and chronic (n = 1) phases. We evaluated clinical courses and prognosis. We measured cytokines/chemokines in cerebrospinal fluid (CSF) from FIRES patients at several points, including pre‐ and post‐IT‐DEX, and compared them with control patients with chronic epilepsy (n = 12, for cytokines/chemokines) or with noninflammatory neurological disease (NIND, n = 13, for neopterin).Results: Anesthesia was weaned after a median of 5.5 days from IT‐DEX initiation (n = 6). There was a positive correlation between the duration from the disease onset to the introduction of IT‐DEX and the length of ICU stay and the duration of mechanical ventilation. No patient experienced severe adverse events. Seizure spreading and background activities on electroencephalography were improved after IT‐DEX in all patients. The levels of CXCL10, CXCL9, IFN‐γ, and neopterin at pre‐IT‐DEX were significantly elevated compared to levels in epilepsy controls, and CXCL10 and neopterin were significantly decreased post‐IT‐DEX, but were still higher compared to patients with chronic epilepsy. IL‐6, IL‐8, and IL‐1β were significantly elevated before IT‐DEX compared to epilepsy controls, though there was no significant decrease post‐treatment.Interpretation: IT‐DEX represents a therapeutic option for patients with FIRES that could shorten the duration of the critical stage of the disease. The effect of IT‐DEX on FIRES might include cytokine‐independent mechanisms.
- 5 February 2021
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 8 (3) , 645-655
Open AccessIntrathecal dexamethasone therapy for febrile infection‐related epilepsy syndrome
Objective: Increasing reports suggest a role for immunological mechanisms in febrile infection‐related epilepsy syndrome (FIRES). The objective of this study was to elucidate the efficacy and safety of intrathecal dexamethasone therapy (IT‐DEX).Methods: We assessed six pediatric patients with FIRES who were administered add‐on IT‐DEX in the acute (n = 5) and chronic (n = 1) phases. We evaluated clinical courses and prognosis. We measured cytokines/chemokines in cerebrospinal fluid (CSF) from FIRES patients at several points, including pre‐ and post‐IT‐DEX, and compared them with control patients with chronic epilepsy (n = 12, for cytokines/chemokines) or with noninflammatory neurological disease (NIND, n = 13, for neopterin).Results: Anesthesia was weaned after a median of 5.5 days from IT‐DEX initiation (n = 6). There was a positive correlation between the duration from the disease onset to the introduction of IT‐DEX and the length of ICU stay and the duration of mechanical ventilation. No patient experienced severe adverse events. Seizure spreading and background activities on electroencephalography were improved after IT‐DEX in all patients. The levels of CXCL10, CXCL9, IFN‐γ, and neopterin at pre‐IT‐DEX were significantly elevated compared to levels in epilepsy controls, and CXCL10 and neopterin were significantly decreased post‐IT‐DEX, but were still higher compared to patients with chronic epilepsy. IL‐6, IL‐8, and IL‐1β were significantly elevated before IT‐DEX compared to epilepsy controls, though there was no significant decrease post‐treatment.Interpretation: IT‐DEX represents a therapeutic option for patients with FIRES that could shorten the duration of the critical stage of the disease. The effect of IT‐DEX on FIRES might include cytokine‐independent mechanisms.
- 1 March 2017
- Published by Elsevier in Brain and Development
- Vol. 39 (3) , 256-260
A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: Clinical features and treatment for epilepsy
- 1 March 2017
- Published by Elsevier in Brain and Development
- Vol. 39 (3) , 256-260
A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: Clinical features and treatment for epilepsy
- 1 October 2016
- Published by Elsevier in Brain and Development
- Vol. 38 (9) , 866-870
A case of succinic semialdehyde dehydrogenase deficiency with status epilepticus and rapid regression
- 1 October 2016
- Published by Elsevier in Brain and Development
- Vol. 38 (9) , 866-870
A case of succinic semialdehyde dehydrogenase deficiency with status epilepticus and rapid regression